CJC-1295 vs Insulin
Overview
CJC-1295 is primarily a performance & growth peptide, while Insulin is used for weight management & metabolic.
This page compares CJC-1295 and Insulin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| CJC-1295 | Insulin | |
|---|---|---|
| Category | Performance & Growth | Weight Management & Metabolic |
| Regulatory status (US) | Research use only | FDA approved |
| Typical dosage | 1-2 mg | Highly individualized; type 1 diabetes basal-bolus regimens typically require 0.5–1.0 units/kg/day total; type 2 diabetes is often initiated with basal insulin at 10 units or 0.1–0.2 units/kg/day, titrated to individual glycemic targets |
| Frequency | weekly | Once daily (long-acting basal analogs) to four or more times daily (basal-bolus or continuous subcutaneous insulin infusion); prandial doses given 0–15 minutes before meals for rapid-acting analogs or 30 minutes before meals for regular human insulin |
| Reported benefits | Increased muscle mass, fat loss, improved recovery, better sleep, enhanced bone density | Glycemic control, prevention of diabetic ketoacidosis, reduction of microvascular complications (retinopathy, nephropathy, neuropathy), life-sustaining therapy in type 1 diabetes, HbA1c reduction in type 2 diabetes |
| Reported side effects | Water retention, joint pain, potential insulin resistance with prolonged use | Hypoglycemia, weight gain, injection-site lipohypertrophy, rare hypersensitivity reactions, peripheral edema at initiation |
Key differences
Primary use. CJC-1295 is categorised under Performance & Growth, while Insulin falls under Weight Management & Metabolic. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. CJC-1295: not FDA-approved; treated as a research compound. Insulin: FDA-approved.
Dosing. CJC-1295 is typically dosed at 1-2 mg (weekly). Insulin is typically dosed at Highly individualized; type 1 diabetes basal-bolus regimens typically require 0.5–1.0 units/kg/day total; type 2 diabetes is often initiated with basal insulin at 10 units or 0.1–0.2 units/kg/day, titrated to individual glycemic targets (Once daily (long-acting basal analogs) to four or more times daily (basal-bolus or continuous subcutaneous insulin infusion); prandial doses given 0–15 minutes before meals for rapid-acting analogs or 30 minutes before meals for regular human insulin).
Can you stack them?
Some protocols combine peptides, but stacking CJC-1295 and Insulin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between CJC-1295 and Insulin?
- CJC-1295 is primarily a performance & growth peptide, while Insulin is used for weight management & metabolic. CJC-1295 is not FDA-approved; generally classified as a research compound, whereas Insulin is FDA-approved for one or more indications.
- What is CJC-1295 used for?
- Growth hormone, muscle mass, fat loss.
- What is Insulin used for?
- The foundational peptide hormone for glycemic management in type 1 and type 2 diabetes mellitus.
- Can you take CJC-1295 and Insulin together?
- Some users combine peptides within a single protocol, but stacking CJC-1295 and Insulin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is CJC-1295 or Insulin FDA-approved?
- CJC-1295 is not FDA-approved; generally classified as a research compound. Insulin is FDA-approved for one or more indications.